Table 1.
Characteristics of included studies.
| Study name | No. of diabetic participants | Demographic characteristics | Intervention | Control | Follow-up (years) |
|---|---|---|---|---|---|
| ASCEND 2018 (6) | 15,480 | Diabetic men and women, > 40 years, diabetes mellitus with no known CV condition | Aspirin (100 mg/day) | Placebo | 7.5 |
| ASPREE 2018 (7) | 2,057 | Men and women, > 70 years, No coronary heart disease, cerebrovascular disease and atrial fibrillation | Aspirin (100 mg/day) | Placebo | 4.7 |
| ETDRS 1992 (8) | 3,711 | Men and women with type 1 and type 2 diabetes, 18-70 years | Aspirin (650 mg/day) | Placebo | 5 |
| JPAD 2008 (9) | 2,539 | Men and women with type 2 diabetes, 30-85 years | Aspirin (81-100 mg/day) | No aspirin | 4.37 |
| JPPP 2014 (10) | 4,903 | Men and women, with diabetes mellitus and dyslipidaemia, 60-85 years, no atherosclerotic disease | Aspirin (100 mg/day) | No aspirin | 5.02 |
| POPADAD 2008 (11) | 1,276 | Men and women with type 1 or type 2 diabetes mellitus, > 40 years, asymptomatic peripheral disease | Aspirin + antioxidant Aspirin+placebo (100 mg/day) |
Placebo | 6.7 |
| PPP 2003 (12) | 1,031 | Men and women with diabetes mellitus and hypertension, hypercholesterolemia > 50 years | Aspirin (100 mg/day) | Vitamin E (300 mg/day) |
3.6 |
| WHS 2005 (13) | 1,027 | Women > 45 years, no history of coronary heart diseases, cerebrovascular disease or cancer | Aspirin (100 mg on alternate days) | Placebo | 10.1 |